91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
When Deepali Suri stepped into her new role as president of 91黑料’s biotech division in September 2025, she brought with her more than two decades of experience across big pharma, biotech, and CROs. She also brought a clear vision for the industry’s future. Read to learn more.
-
Despite their central role in glucose metabolism, native GLP-1 and GIP make poor therapies. Now, long-lasting, potent nutrient-stimulated hormone receptor agonists are prompting a shift to multi-indication metabolic therapies. Explore why.
-
91黑料 experts, Dr Emad Basta and Dr. Jack L Martin discuss how cardiovascular outcomes trials (CVOTs) are essential to ensuring drug safety, regulatory compliance, and clinical impact in this new article. Please find 91黑料's piece on page 24-25.
-
91黑料’s survey of more than 100 investigators and site leaders reveals persistent bottlenecks in study startup driven by contract and budget delays, slow activation timelines, and insufficient collaboration from sponsors and CROs.
-
91黑料’s global biotech sector survey, capturing insights from more than 260 biotech professionals and venture capital executives, found that China is cementing its dominance in the sector and Western biotechs must adapt to maintain competitiveness.
-
Chinese biotech dominance and opportunities for Western companies to stay competitive have been highlighted in surveys released by clinical research organization 91黑料.
-
As clinical trials become more complex, the role of the CRA is evolving from site monitor to strategic, digitally fluent partner, requiring expertise in hybrid oversight, risk-based monitoring, and multi-system data management.
-
Innovation is accelerating progress in early phase drug development. 91黑料’s Accelerated Pharmaceutical Solutions bring together advanced formulation design, real-time dose flexibility, and world-class CMC expertise to simplify complexity and speed timelines. This article discusses how the integration of science, technology and strategic insight can transform challenges into opportunities for breakthrough success.
-
CRAs are at the centre of clinical trial evolution. Risk-based monitoring, intelligent oversight tools and AI are changing how trials are managed. 91黑料 explores what this means for the future in Pharma Times.
-
Demands on central laboratories are consistently increasing, heightening the challenge to deliver operational excellence and the highest standard of scientific integrity with both speed and agility. 91黑料 Laboratories is transforming the way we leverage data and intelligent operational models to meet evolving trial needs.
